Creatine Supplementation During GLP-1a Therapy

Sponsor
University of Saskatchewan
Study ID
NCT07625202
Status
Recruiting
Apply to this trial

Conditions

  • Sarcopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Dietary supplementation during a 12 week resistance-training program (creatine) — DIETARY_SUPPLEMENT
    creatine supplementation
  • Dietary supplementation during a 12 week resistance-training program (placebo) — DIETARY_SUPPLEMENT
    Placebo

Study Details

GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.

Key Dates

First listed
Jun 4, 2026
Start date
May 25, 2026
Status verified
May 2026
Primary completion
May 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Creatine
    10 grams per day creatine
  • Placebo Comparator: Placebo
    Placebo (maltodextrin)

Primary Outcome Measure

Change in sit to stand performance (number of times) [ Time Frame: 12 weeks ]

Central Contacts

Related Studies